CMPK1 and neoplasm: CYL-02 utilizes plasmid DNA containing genes for somatostatin receptor 2 (SSTR2), deoxycytidine kinase (DCK), and uridylate monophosphate kinase (UMK), which together aim to restore gene function in PDAC cells while also sensitizing the tumor to gemcitabine [167].